Emisphere is charting new frontiers in drug delivery. The Company's core business strategy is to use its proprietary Eligen® Technology to develop novel oral forms of injectable drugs or poorly absorbed compounds.

The broadly applicable Eligen® Technology and Emisphere’s current product candidates in the pipeline represent the foundation of the Company’s value proposition and create significant opportunities for growth. Emisphere’s pipeline includes product candidates that have reached clinical development as well as a variety of preclinical research and development programs.  Emisphere is carrying out these programs both in collaboration with pharmaceutical and biotechnology companies and independently. Promising products in the pipeline include an improved formulation of oral Vitamin B12 and oral GLP-1 analogues for Type 2 diabetes (with partner Novo Nordisk A/S). Learn more about our Product Pipeline here.



Copyright © Emisphere, All rights reserved